Trending Topic

Breast Cancer
29 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Endocrine therapy (ET) has changed the natural history of hormone receptor-positive (HR+) breast cancer (BC) and is the cornerstone of the treatment of HR+ BC. There are several ETs approved for the treatment of BC, including selective oestrogen receptor modulators (SERMs; tamoxifen), aromatase inhibitors (AIs; anastrazole, letrozole and exemestane) and selective oestrogen receptor degraders (SERDs; fulvestrant […]

Srdan Verstovsek, ASH 2022: Momelotinib long-term safety in myelofibrosis disease – Analysis of SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM trials

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Jan 4th 2023

Momelotinib, an oral JAK1/JAK2/ACVR1 inhibitor, was evaluated in 3 randomised controlled trials – SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM, in patients with high- and intermediate-risk myelofibrosis. In this touchONCOLOGY interview, we speak with Prof. Srdan Verstovsek (MD Anderson Cancer Center, Houston, TX, USA) to discuss the limitations of JAK inhibitor therapy in myelofibrosis, and the integrated analysis of momelotinib that characterized its long-term safety, with pooled data from the three trials, which represented a spectrum of myelofibrosis disease from early (JAK inhibitor-naive) to late (JAK inhibitor-experienced) stages.

The abstract entitled ‘Momelotinib (MMB) Long-Term Safety: Pooled Data from Three Phase 3 Randomized-Controlled Trials (RCTs)’ (Abstract #4348) was presented at 64th ASH Annual Meeting and Exposition, December 10-13 2022, New Orleans, LA, USA

  1. What are the current limitations of JAK inhibitor therapy in myelofibrosis, and how does the mechanism of action of momelotinib potentially overcome these limitations? (0:12)
  2. Could you give us a brief overview of the SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM clinical trials in patients with high- and intermediate-risk myelofibrosis? (2:27)
  3. What do you see as the future of JAK inhibitors in myelofibrosis? (4:54)

Disclosures: Srdan Verstovsek has nothing to disclose in relation to this video interview.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.

Filmed as a highlight of ASH 2022

Access more content on haematological malignancies

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied

This Functionality is for
Members Only

Explore the latest in medical education and stay current in your field. Create a free account to track your learning.

Close Popup